1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pneumoconiosis Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pneumoconiosis Market, by Type
8.1.1. Asbestosis
8.1.1.1. Market Revenue and Forecast
8.1.2. Silicosis
8.1.2.1. Market Revenue and Forecast
8.1.3. Coal Workers' Pneumoconiosis (CWP)
8.1.3.1. Market Revenue and Forecast
8.1.4. Others (Berylliosis, Byssinosis)
8.1.4.1. Market Revenue and Forecast
9.1. Pneumoconiosis Market, by Diagnostic Method
9.1.1. Chest X-ray
9.1.1.1. Market Revenue and Forecast
9.1.2. CT Scan
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. Pneumoconiosis Market, by Treatment Type
10.1.1. Medications
10.1.1.1. Market Revenue and Forecast
10.1.2. Pulmonary Rehabilitation
10.1.2.1. Market Revenue and Forecast
10.1.3. Others (Oxygen Therapy, Surgery)
10.1.3.1. Market Revenue and Forecast
11.1. Pneumoconiosis Market, by End-User
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Specialty Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Diagnostic Centers
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type
12.1.2. Market Revenue and Forecast, by Diagnostic Method
12.1.3. Market Revenue and Forecast, by Treatment Type
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type
12.1.5.2. Market Revenue and Forecast, by Diagnostic Method
12.1.5.3. Market Revenue and Forecast, by Treatment Type
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type
12.1.6.2. Market Revenue and Forecast, by Diagnostic Method
12.1.6.3. Market Revenue and Forecast, by Treatment Type
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type
12.2.2. Market Revenue and Forecast, by Diagnostic Method
12.2.3. Market Revenue and Forecast, by Treatment Type
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type
12.2.5.2. Market Revenue and Forecast, by Diagnostic Method
12.2.5.3. Market Revenue and Forecast, by Treatment Type
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type
12.2.6.2. Market Revenue and Forecast, by Diagnostic Method
12.2.6.3. Market Revenue and Forecast, by Treatment Type
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type
12.2.7.2. Market Revenue and Forecast, by Diagnostic Method
12.2.7.3. Market Revenue and Forecast, by Treatment Type
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type
12.2.8.2. Market Revenue and Forecast, by Diagnostic Method
12.2.8.3. Market Revenue and Forecast, by Treatment Type
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type
12.3.2. Market Revenue and Forecast, by Diagnostic Method
12.3.3. Market Revenue and Forecast, by Treatment Type
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type
12.3.5.2. Market Revenue and Forecast, by Diagnostic Method
12.3.5.3. Market Revenue and Forecast, by Treatment Type
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type
12.3.6.2. Market Revenue and Forecast, by Diagnostic Method
12.3.6.3. Market Revenue and Forecast, by Treatment Type
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type
12.3.7.2. Market Revenue and Forecast, by Diagnostic Method
12.3.7.3. Market Revenue and Forecast, by Treatment Type
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type
12.3.8.2. Market Revenue and Forecast, by Diagnostic Method
12.3.8.3. Market Revenue and Forecast, by Treatment Type
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type
12.4.2. Market Revenue and Forecast, by Diagnostic Method
12.4.3. Market Revenue and Forecast, by Treatment Type
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type
12.4.5.2. Market Revenue and Forecast, by Diagnostic Method
12.4.5.3. Market Revenue and Forecast, by Treatment Type
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type
12.4.6.2. Market Revenue and Forecast, by Diagnostic Method
12.4.6.3. Market Revenue and Forecast, by Treatment Type
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type
12.4.7.2. Market Revenue and Forecast, by Diagnostic Method
12.4.7.3. Market Revenue and Forecast, by Treatment Type
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type
12.4.8.2. Market Revenue and Forecast, by Diagnostic Method
12.4.8.3. Market Revenue and Forecast, by Treatment Type
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type
12.5.2. Market Revenue and Forecast, by Diagnostic Method
12.5.3. Market Revenue and Forecast, by Treatment Type
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type
12.5.5.2. Market Revenue and Forecast, by Diagnostic Method
12.5.5.3. Market Revenue and Forecast, by Treatment Type
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type
12.5.6.2. Market Revenue and Forecast, by Diagnostic Method
12.5.6.3. Market Revenue and Forecast, by Treatment Type
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. AstraZeneca PLC
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Boehringer Ingelheim International GmbH
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. F. Hoffmann-La Roche Ltd.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. GlaxoSmithKline plc (GSK)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Lupin Limited
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Merck & Co., Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novartis AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Pfizer Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Sanofi S.A.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Teva Pharmaceutical Industries Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
